A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face ...

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...

A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...